BISPECIFIC ANTIBODY
Phase II DeLLphi-301 Study Reveals Impressive Antitumor Activity of Amgen’s First-in-Class Bispecific Antibody Tarlatamab (ESMO 2023)
Anika Sharma
ESMO 2023: LBA92 Most SCLC patients are diagnosed with cancer that has already spread beyond the lungs, and their average ...
Roche’s Vabysmo Preserves RVO Patients’ Vision with 4-Month Treatment Intervals in Phase III Trials
Anika Sharma
Roche has unveiled promising long-term findings from the global phase III BALATON and COMINO trials, which investigated the extended treatment ...
Carvykti CAR-T Therapy by J&J and Legend Biotech Persists Amid New Bispecific
Anika Sharma
Johnson & Johnson and Legend Biotech’s Carvykti maintains growth in the multiple myeloma market despite the emergence of a more ...
Pfizer’s Elrexfio Gets FDA Nod, Ignites Showdown with J&J in Multiple Myeloma Arena
SG Tylor
Pfizer’s latest BCMA-targeted drug, Elrexfio (elranatamab), has gained FDA approval for treating multiple myeloma patients who have undergone at least ...
Epkinly: FDA-Approved Bispecific Antibody for DLBCL
SG Tylor
On May 19, 2023, AbbVie announced that the U.S. Food and Drug Administration (FDA) granted approval to EPKINLYTM (epcoritamab-bysp) as ...
